Skip to main content
Clinical Trials/NCT03082495
NCT03082495
Completed
Not Applicable

A Phase II Randomized Controlled Trial of Aerobic Exercise in Rectal Cancer Patients During and After Neoadjuvant Chemoradiotherapy

University of Alberta1 site in 1 country36 target enrollmentJune 26, 2017
ConditionsRectal Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Cancer
Sponsor
University of Alberta
Enrollment
36
Locations
1
Primary Endpoint
Change in Cardiorespiratory fitness
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study is designed to investigate if aerobic exercise during and after neoadjuvant chemoradiotherapy (NACRT) can improve outcomes for rectal cancer patients.

Detailed Description

The EXERT trial is a single-center, prospective, two-armed, phase II randomized controlled trial designed to test the preliminary efficacy of exercise training in this clinical setting and to further evaluate its feasibility and safety. Participants will be 60 rectal cancer patients scheduled to receive long-course NACRT followed by total mesorectal excision. Participants will be randomly assigned to exercise training or usual care. Participants in the exercise training group will be asked to complete three supervised, high-intensity interval training sessions/week during NACRT and ≥ 150 min/week of unsupervised, moderate-to-vigorous-intensity, continuous exercise training after NACRT prior to surgery. Participants in the usual care group will be asked not to increase their exercise from baseline. Assessments will be completed pre NACRT, post NACRT, and pre surgery. The primary endpoint will be cardiorespiratory fitness (VO2 peak) at the post-NACRT time point assessed by a graded exercise test. Secondary endpoints will include functional fitness, quality of life, and symptom management. Exploratory clinical endpoints will include treatment toxicities, treatment completion, treatment response, and surgical complications.

Registry
clinicaltrials.gov
Start Date
June 26, 2017
End Date
September 1, 2020
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients scheduled to receive long-course (5-6 weeks) of NACRT followed by total mesorectal excision

Exclusion Criteria

  • Unable to consent
  • Unable to perform aerobic exercise
  • Intention to engage in a structured exercise program during NACRT and/or after NACRT and prior to surgery

Outcomes

Primary Outcomes

Change in Cardiorespiratory fitness

Time Frame: pre-NACRT (baseline), post-NACRT (an average of 6 weeks)

VO2 peak

Secondary Outcomes

  • Cardiorespiratory fitness(pre-surgery (an average of 12 weeks))
  • Functional fitness(pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Generic quality of life(pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Disease specific quality of life(pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Symptom burden(pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Exercise motivation(pre-NACRT (baseline), post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Eligibility rate(up to 20 months)
  • Recruitment rate(up to 20 months)
  • Exercise adherence rate(post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Follow-up assessment rate(post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))
  • Safety: Adverse event rate(post-NACRT (an average of 6 weeks), pre-surgery (an average of 12 weeks))

Study Sites (1)

Loading locations...

Similar Trials